Document is current
Any future updates will be listed below
-
Authors
Yin, Mingzhu
Guo, Ying
Hu, Rui
Cai, Wesley L.
Li, Yao
Pei, Shiyao
Sun, Hongyin
Peng, Cong
Li, Jiali
Ye, Rui https://orcid.org/0000-0002-4021-8093
Yang, Qiaohong
Wang, Nenghui
Tao, Yongguang https://orcid.org/0000-0003-2354-5321
Chen, Xiang https://orcid.org/0000-0001-8187-636X
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81874138, 81728014)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-15-1-0117)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA121974, R01CA237586)
Melanoma Research Alliance (The Sokoloff Family-MRA Team Science Award)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 6 June 2018
Accepted: 27 February 2020
First Online: 14 April 2020
Competing interests
: N.W. is the founder of Ningbo Wenda Pharma. Other authors declare no competing interests.
